Abstract 5678
Background
Hepatocellular carcinoma (HCC) has relatively sensitive and specific serum tumor antigen markers (AFP), which is also the most common serological marker for cancer screening. However, there are unignorable limitations, including possible false-negatives/positives owing to confounding conditions. Reliable non-invasive diagnostics is still in urgent need. This work proposes a novel LDI-TOF-MS technique for HCC screening and diagnosis. By taking advantage of 3D nanostructures and machine learning, our technique enables high fidelity and reproducibility.
Methods
An LDI-TOF-MS platform was established for HCC screening and was applied to 139 patients with liver cancer, as well as 203 healthy controls (Table). All mass spectrum was collected within a mass range of 100 to 1,100 Da for metabolites. Based on the data acquired by LDI-TOF-MS, SVM algorithm was developed and applied for automated cancer classification across six cancer types, which was further validated by single blinded samples with randomly selected cancer patients and controls.Table: 1432P
Summary of patient and healthy control characteristics
Patient Type | N | Gender | Gender | Age | AJCC Stage | AJCC Stage | AJCC Stage | AJCC Stage |
---|---|---|---|---|---|---|---|---|
M(%) | F(%) | I | II | III | IV | |||
HCC | 139 | 120 (86.33%) | 19 (13.67%) | 55.63± 11.22(25-80) | 51 | 48 | 40 | - |
HC | 203 | 117 (57.64%) | 86 (42.36%) | 47.68± 10.78(23-76) | - | - | - | - |
Results
This assay demonstrated an average sensitivity of 96% and a specificity over 98% in detecting HCC. In our cohort, 47 of 137 HCC patients (35.77%) were AFP negative (AFP<20ng/ml, stage I n = 18, stage II n = 17 and stage III n = 12). Here, we showed that the LDI-TOF-MS recognized almost all AFP-negative HCC. The sensitivity and specificity were obviously superior to AFP in HCC: only 2 of 137 HCCs (1.46%) were misclassified as healthy controls. In contrast, AFP positive and AFP negative HCCs were not readily distinguished by this method. Therefore, this method was independent of tumor markers.
Conclusions
This work established a low-cost, high-throughput procedure based on trace amount of serum to identify HCC as well as healthy controls with superior precision, making it a promising technique for clinical cancer research and translation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhongshan Hospital, Fudan University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5650 - Tissue-based activation of mucosal-associated invariant T (MAIT) cells in combination ipilimumab and nivolumab checkpoint inhibitor (CI) colitis.
Presenter: Sarah Sasson
Session: Poster Display session 3
Resources:
Abstract
5944 - Significance of severe immune-related adverse effects (irAE) on patients with advanced tumors treated with immune checkpoint inhibitors being admitted for secondary toxicity: Clinical relevance and next steps
Presenter: Leyre Zubiri
Session: Poster Display session 3
Resources:
Abstract
5989 - Implementation of a dedicated immuno-oncology toxicity service reduces the acute impact of immune-related adverse events
Presenter: Anna Olsson-Brown
Session: Poster Display session 3
Resources:
Abstract
3267 - Cardiotoxic and pro-inflammatory effects induced by the association of immune checkpoint inhibitor Pembrolizumab and Trastuzumab in preclinical models
Presenter: Nicola Maurea
Session: Poster Display session 3
Resources:
Abstract
3417 - Interstitial lung disease associated with immune-checkpoint inhibitors in malignant diseases
Presenter: Akira Yamagata
Session: Poster Display session 3
Resources:
Abstract
2071 - A Phase 1 Study of Intraperitoneal MCY-M11 Anti-Mesothelin CAR for Women with Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects with Peritoneal Mesothelioma with Recurrence after Prior Chemotherapy
Presenter: Christina Annunziata
Session: Poster Display session 3
Resources:
Abstract
4935 - Trial in progress: First-in-human study of a novel anti-NY-ESO-1–anti-CD3, TCR-based bispecific (IMCnyeso) as monotherapy in NY-ESO-1/LAGE-1A-positive advanced solid tumors (IMCnyeso-101)
Presenter: Juanita Lopez
Session: Poster Display session 3
Resources:
Abstract
5613 - Nimotuzumab-Cisplatin-Radiation versus Cisplatin-Radiation in HPV negative oropharyngeal cancer
Presenter: Kumar Prabhash
Session: Poster Display session 3
Resources:
Abstract
2576 - Interim analysis of a single arm phase 2 study of adjuvant nivolumab after salvage resection in head and neck squamous cell carcinoma patients previously treated with definitive therapy.
Presenter: Trisha Wise-draper
Session: Poster Display session 3
Resources:
Abstract
4758 - A Phase I Study of the CDK4/6 Inhibitor, Palbociclib in combination with Cetuximab and Intensity Modulated Radiation Therapy (IMRT) for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN); A Result of Dose Escalation Cohort
Presenter: Nuttapong Ngamphaiboon
Session: Poster Display session 3
Resources:
Abstract